Cambridge Healthtech Institute’s 4th Annual

Combination Immunotherapy

Distinguishing Promising Cancer Immunotherapy Combinations from the Crowd

20-21 March 2019

 

TTreating cancer patients with an immunological combination is an essential strategy that is still growing in popularity. With so many trials ongoing though, it can all get a bit confusing. There are many factors that may influence therapeutic success, including but not limited to double immunotherapy combinations or immune checkpoint inhibitors combined with conventional cancer therapy. Predictive biomarkers, novel antigens, therapeutic mechanism, reducing toxicity and the immune response are all important considerations. This and more will be discussed in at the Combination Immunotherapy conference.

Preliminary Agenda

Antibody and Checkpoint Inhibitor Combinations

KEYNOTE PRESENTATION: PD-1 Antibodies Are Transforming Cancer Therapy Both as Mono- and Combination Therapies

Roy Baynes, MD, Senior Vice President, Global Clinical Development & CMO, Merck Research Labs

Dual-Targeting Bispecific Antibodies for CD47 Blockade in Cancer

Krzysztof Masternak, PhD, Head of Biology, Biology, NovImmune

On the Requirement to Induce Immune Modulation Prior to Checkpoint Inhibitor Therapy; Lessons from Mice and Men

Angus Dalgleish, MD, Professor, Oncology & Infection & Immunity, St George’s Hospital

Multiple Immunotherapy Combinations

The Exercise of TAMing the Immune System

Per Thor Straten, MD, Clinical Professor, Department of Immunology and Microbiology, University of Copenhagen

Next Generation Cancer Immunotherapy

Daniel Chen, MD, CMO, IGM Bioscience

Novel RNA-Transfected Dendritic Cells as a Universal Vaccine Platform to Induce T Cells Recognizing Shared Antigens as well as Mutated and Non-Mutated Neoantigens

Gerold Schuler, MD, Professor and Head of the clinic, Dermatologic and STD Clinic, Universitätsklinikum Erlangen

NK Cell-Based Therapy for the Treatment of Membrane Hsp70 Tumours

Graham Pockley, PhD, Director and Professor Immunobiology, John van Geest Cancer Research Centre, Nottingham Trent University; CEO, multimmune GmbH

Dendritic Cells, the Key to Immuno-Oncology

Thomas Nesselhut, MD, Founder, Meridian Medical Group

Targeting TNFR Family Members. Challenges and Opportunities

Mark Cragg, MD, Professor & Chair Experimental Cancer Biology, Antibody & Vaccine Group, Southampton General Hospital




For more details on the conference, please contact:
Joel Hornby, BSc Hons

Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781 247 1816
Email: jhornby@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com